Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114378 | 0.90 | NAALAD2 (0.45) | NAALAD2DPP4DPP8DPP9FOLH1 | |
| SCHEMBL29601993 | 0.87 | NTSR2 (0.40) | NAALAD2CPB2OPRM1NTSR2NTSR1 | |
| SCHEMBL29466112 | 0.86 | F2 (0.41) | OPRM1ACE | |
| SCHEMBL31114275 | 0.86 | NAALAD2 (0.44) | NAALAD2DPP4DPP8DPP9FOLH1 | |
| SCHEMBL29720815 | 0.85 | NAALAD2 (0.46) | NAALAD2FOLH1CPB2 | |
| SCHEMBL4440604 | 0.84 | ATM (0.50) | NAALAD2FOLH1CPB2 | |
| SCHEMBL4440608 | 0.84 | ATM (0.50) | NAALAD2FOLH1CPB2 | |
| SCHEMBL31114523 | 0.84 | NRP1 (0.44) | NAALAD2DPP4DPP8DPP9OPRM1 | |
| SCHEMBL29663741 | 0.82 | ACE (0.51) | CPB2OPRM1NTSR2NTSR1ACE | |
| SCHEMBL29752649 | 0.81 | NTSR2 (0.43) | NAALAD2OPRM1NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | VIP, MLX, IAPP | NAALAD2 793/4885DPP4 423/4885DPP8 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.